Pharmacologic use of glucocorticoids
- Lynnette K Nieman, MD
Lynnette K Nieman, MD
- Section Editor — Adrenal Disease
- Senior Investigator
- Bethesda, MD
Natural and synthetic glucocorticoids are used in both endocrine and nonendocrine disorders.
●In endocrine practice, glucocorticoids are given only to establish the diagnosis and cause of Cushing's syndrome and for treatment of adrenal insufficiency using physiologic replacement doses and for treatment of congenital adrenal hyperplasia, for which the dose and schedule may not by physiologic.
●Pharmacologic (usually supraphysiologic) doses of glucocorticoids are used to treat patients with inflammatory, allergic, and immunological disorders. If chronic, this supraphysiologic therapy has many adverse effects, ranging from suppression of the hypothalamic-pituitary-adrenal (HPA) axis and Cushing's syndrome to infections and changes in mental status. (See "Major side effects of systemic glucocorticoids".)
A number of factors that influence both the therapeutic and adverse effects of glucocorticoids will be reviewed here, including the biologic potency, pharmacokinetic properties of the glucocorticoid, daily dose, timing of doses during the day, individual differences in steroid metabolism, and the duration of treatment (table 1).
Other issues, including the determinants of steroid dosing and the approach to glucocorticoid withdrawal to prevent adrenal insufficiency and minimize the likelihood of recurrent activity of the underlying disease are discussed separately. (See "Determinants of glucocorticoid dosing" and "Glucocorticoid withdrawal".)
Subscribers log in hereLiterature review current through: Nov 2017. | This topic last updated: Feb 15, 2017.References
- Dluhy RG, Newmark SR, Lauler DP, Thorn GW. Pharmacology and chemistry of adrenal glucocorticoids. In: Steroid therapy, Azarnoff DL (Ed), WB Saunders, Philadelphia 1975. p.1.
- Christy NP. Principles of systemic corticosteroid therapy in nonendocrine disease. In: Current Therapy in Endocrinology and Metabolism, 3rd Ed, Bardin CW (Ed), BC Decker, New York 1988. p.104.
- HERZOG HL, NOBILE A, TOLKSDORF S, et al. New antiarthritic steroids. Science 1955; 121:176.
- STAFFORD RO, BARNES LE, BOWMAN BJ, MEINZINGER MM. Glucocorticoid and mineralocorticoids activities of delta1-fluorohydrocortisone. Proc Soc Exp Biol Med 1955; 89:371.
- Migeon CJ, Lawrence B, Bertrand J, Holman GH. In vivo distribution of some 17-hydroxycorticoids between the plasma and red blood cells of man. J Clin Endocrinol Metab 1959; 19:1411.
- Pugeat MM, Dunn JF, Nisula BC. Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53:69.
- Ballard PL. Delivery and transport of glucocorticoids to target cells. In: Glucocorticoid Hormone Action, Baxter JD, Rousseau GG (Eds), Springer-Verlag, Berlin 1979. p.25.
- NUGENT CA, EIK-NES K, SAMUELS LT, TYLER FH. Changes in plasma levels of 17-hydroxycorticosteroids during the intravenous administration of adrenocorticotropin (ACTH). IV. Response to prolonged infusions of small amounts of ACTH. J Clin Endocrinol Metab 1959; 19:334.
- PETERSON RE. Metabolism of adrenocorticosteroids in man. Ann N Y Acad Sci 1959; 82:846.
- Diederich S, Eigendorff E, Burkhardt P, et al. 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 2002; 87:5695.
- Youssef DM, Attia TA, El-Shal AS, Abduelometty FA. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids. Gene 2013; 530:201.
- Koetz KR, van Rossum EF, Ventz M, et al. BclI polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 2013; 78:831.
- Giordano R, Marzotti S, Berardelli R, et al. BClI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison's disease. Clin Endocrinol (Oxf) 2012; 77:863.
- BURSTEIN S, KLAIBER EL. PHENOBARBITAL-INDUCED INCREASE IN 6-BETA-HYDROXYCORTISOL EXCRETION: CLUE TO ITS SIGNIFICANCE IN HUMAN URINE. J Clin Endocrinol Metab 1965; 25:293.
- WERK EE Jr, MACGEE J, SHOLITON LJ. EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN. J Clin Invest 1964; 43:1824.
- Yamada S, Iwai K. Letter: Induction of hepatic cortisol-6-hydroxylase by rifampicin. Lancet 1976; 2:366.
- BLEDSOE T, ISLAND DP, NEY RL, LIDDLE GW. AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN. J Clin Endocrinol Metab 1964; 24:1303.
- Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39:1.
- Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 1977; 63:200.
- LIDDLE GW. Studies of structure-function relationships of steroids. II. The 6 alpha-methylcorticosteroids. Metabolism 1958; 7:405.
- DULIN WE. Anti-inflammatory activity of delta1-9alpha-fluorohydrocortisone acetate. Proc Soc Exp Biol Med 1955; 90:115.
- SOFFER LJ, ORR RH. Symposium: newer hydrocortisone analogs. Metabolism 1958; 7:383.
- DULIN WE, BARNES LE, GLENN EM, et al. Biologic activities of some C21 steroids and some 6 alpha-methyl C21 steroids. Metabolism 1958; 7:398.
- Meikle AW, Weed JA, Tyler FH. Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunogassays. J Clin Endocrinol Metab 1975; 41:717.
- Yokoyama H, Takabatake T, Takaeda M, et al. Up-regulated MHC-class II expression and gamma-IFN and soluble IL-2R in lupus nephritis. Kidney Int 1992; 42:755.
- Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998; 41:761.
- Kehlet H, Binder C, Blichert-Toft M. Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin Endocrinol (Oxf) 1976; 5:37.
- Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501.
- Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1:542.
- Ng PC, Fok TF, Wong GW, et al. Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab 1998; 83:2390.
- Fisher DA. Adverse effects of topical corticosteroid use. West J Med 1995; 162:123.
- FELDMANN RJ, MAIBACH HI. PENETRATION OF 14C HYDROCORTISONE THROUGH NORMAL SKIN: THE EFFECT OF STRIPPING AND OCCLUSION. Arch Dermatol 1965; 91:661.
- Feiwel M, James VH, Barnett ES. Effect of potent topical steroids on plasma-cortisol levels of infants and children with eczema. Lancet 1969; 1:485.
- Garber EK, Fan PT, Bluestone R. Realistic guidelines in corticosteroid therapy of rheumatic disease. Semin Arthritis Rheum 1981; 11:231.
- Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993; 119:963.
- HARTER JG, REDDY WJ, THORN GW. STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN. N Engl J Med 1963; 269:591.
- Fauci AS. Alternate-day corticosteroid therapy. Am J Med 1978; 64:729.
- STRUCTURES OF COMMON SYNTHETIC STEROIDS
- Plasma disappearance half-life
- Activation and inactivation in target cells
- Assays of biologic activity
- CRITERIA FOR INITIATING THERAPY
- Medical emergencies
- Chronic therapy
- ROUTE OF ADMINISTRATION
- Parenteral therapy
- Oral administration
- Nonsystemic administration
- Alternate-day administration
- COMPLICATIONS OF CHRONIC USE
- HPA axis suppression
- Cushing's syndrome (iatrogenic)
- MINIMIZING GLUCOCORTICOID SIDE EFFECTS
- INFORMATION FOR PATIENTS